Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.






Home » Drug Information » FDA-Approved Drugs » 1996
Medical Areas: Cardiology/Vascular Diseases

View By: Year Company Therapeutic Areas Drug Names 

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: Retavase (reteplase)

Company: Boehringer Mannheim Corporation
Approval Status: Approved November 1996
Treatment Area: patients suffering from heart attack

General Information

Retavase (reteplase), a new thrombolytic agent to help treat the 1.5 million American subjects suffering from heart attack each year, has been approved. Retavase is the only thrombloytic that can be given in a simple two-shot form rather than a continuous intravenous infusion.

Clinical Results

An international study of more than 6,000 subjects treated with either Retavase or streptokinase proved Retavase to be safe and effective in reducing mortality and lowering the incidence of CHF and other cardiovascular conditions. Additionally, clinical data show that Retavase was associated with a reduced need to perform emergency angioplasty compared to Alteplase.

Additional Information

Thrombolytic agents are used to treat patents that suffer from heart attack, or what is medically known as acute myocardial infarction (AMI). Widespread research has shown that one of the most effective treatments for a heart attack as a result of blockage caused by a blood clot is to quickly administer a thrombolytic agent to restore blood flow to the affected artery.


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.